TY - JOUR
T1 - Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
AU - Nasser, Nicola J.
AU - Klein, Jonathan
AU - Agbarya, Abed
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2021/1/1
Y1 - 2021/1/1
N2 - The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.
AB - The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.
UR - http://www.scopus.com/inward/record.url?scp=85098493903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098493903&partnerID=8YFLogxK
U2 - 10.1016/j.adro.2020.10.016
DO - 10.1016/j.adro.2020.10.016
M3 - Review article
AN - SCOPUS:85098493903
SN - 2452-1094
VL - 6
JO - Advances in Radiation Oncology
JF - Advances in Radiation Oncology
IS - 1
M1 - 100603
ER -
